ROS1

David Hung Medivation CEO

Pharma

With lung cancer FDA nod, it's David versus Goliath

Nuvation Bio has won FDA approval for Ibtrozi, or taletrectinib, to challenge existing meds from Pfizer, BMS and Roche in ROS1-positive lung cancer.

Angus Liu Jun 11, 2025 4:17pm

Roche

Ready to rumble: Roche scores Rozlytrek OK to challenge Bayer

Aug 15, 2019 5:11pm